# Australian Technical Advisory Group on Immunisation (ATAGI)

## Summary of the 112th meeting, 9 April 2025

### Respiratory syncytial virus (RSV)

* ATAGI endorsed the GRADE Evidence to Decision assessment for nirsevimab, a long-acting monoclonal antibody against RSV. [ATAGI’s recommendations for RSV prevention in infants](https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv#infants-and-children) are on the Australian Immunisation Handbook website.
* Australia’s RSV prevention program includes free RSV vaccine under the National Immunisation Program (NIP) for eligible pregnant people from 28 weeks of gestation to protect their newborn baby from RSV, and free nirsevimab for eligible infants through state and territory funded programs. These immunisation products will help protect newborn babies from RSV.
* The [clinical guidance on RSV immunisation product administration errors](https://ncirs.org.au/ncirs-clinical-guidance-rsv-immunisation-product-administration-errors) provides advice on the management of a range of possible administration errors, including when a repeat dose is needed. This document will incorporated into the Australian Immunisation Handbook chapter on RSV in the next scheduled update.

### Measles

* ATAGI noted with concern the ongoing notifications of measles in Australia and overseas.
* ATAGI emphasised the importance of receiving every dose of every vaccine in the childhood schedule on time to protect young children against serious diseases.

### Other ATAGI business

* ATAGI reviewed and discussed a draft targeted review on immunisation for people who are immunocompromised.

### Resources

* ATAGI’s membership, terms of reference and declaration of interest information is available on the [Department of Health and Aged Care website](https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi?language=und).